Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Stem Cell Investigation
|
July 1, 2016
The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute
Jilong Yang, Zhiwu Ren, Xiaoling Du, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
February 6, 2016
Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China
Mengze Hao, Gang Zhao, Xiaoling Du, et al.
Discovery Medicine
|
July 1, 2014
Advances in targeted therapy for osteosarcoma
Wenya Zhou, Mengze Hao, Xiaoling Du, et al.
Cancer Letters
|
January 13, 2015
Advances in targeted therapy for unresectable melanoma: new drugs and combinations
Mengze Hao, Fengju Song, Xiaoling Du, et al.
Oncotargets and Therapy
|
December 25, 2023
Post-HSCT Maintenance Treatment Using Entrectinib for an AML Patient Accompanied with ETV6::NTRK3: A Case Report
Xiaoli Zhao, Mengze Hao, Xiaoyu Zhang, et al.
Frontiers in Immunology
|
December 4, 2025
Allogeneic hematopoietic stem cell transplantation for mixed-phenotype acute leukemia: a single-center study
Mengze Hao, Xiaoli Zhao, Xiaoyu Zhang, et al.
Frontiers in Pharmacology
|
July 22, 2022
Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation
Xiaoyu Zhang, Xiaoli Zhao, Yuyan Shen, et al.
Bone Marrow Transplantation
|
April 5, 2024
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients
Xiaoyu Zhang, Xiaoli Zhao, Shulian Chen, et al.
Frontiers in Immunology
|
September 2, 2024
Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemia
Lining Zhang, Jianping Li, Weiru Liang, et al.
Cancer Letters
|
March 3, 2020
IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma
Ting Li, Chao Zhang, Gang Zhao, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Stem Cell Investigation
|
July 1, 2016
The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute
Jilong Yang, Zhiwu Ren, Xiaoling Du, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
February 6, 2016
Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China
Mengze Hao, Gang Zhao, Xiaoling Du, et al.
Discovery Medicine
|
July 1, 2014
Advances in targeted therapy for osteosarcoma
Wenya Zhou, Mengze Hao, Xiaoling Du, et al.
Cancer Letters
|
January 13, 2015
Advances in targeted therapy for unresectable melanoma: new drugs and combinations
Mengze Hao, Fengju Song, Xiaoling Du, et al.
Oncotargets and Therapy
|
December 25, 2023
Post-HSCT Maintenance Treatment Using Entrectinib for an AML Patient Accompanied with ETV6::NTRK3: A Case Report
Xiaoli Zhao, Mengze Hao, Xiaoyu Zhang, et al.
Frontiers in Immunology
|
December 4, 2025
Allogeneic hematopoietic stem cell transplantation for mixed-phenotype acute leukemia: a single-center study
Mengze Hao, Xiaoli Zhao, Xiaoyu Zhang, et al.
Frontiers in Pharmacology
|
July 22, 2022
Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation
Xiaoyu Zhang, Xiaoli Zhao, Yuyan Shen, et al.
Bone Marrow Transplantation
|
April 5, 2024
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients
Xiaoyu Zhang, Xiaoli Zhao, Shulian Chen, et al.
Frontiers in Immunology
|
September 2, 2024
Comparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemia
Lining Zhang, Jianping Li, Weiru Liang, et al.
Cancer Letters
|
March 3, 2020
IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma
Ting Li, Chao Zhang, Gang Zhao, et al.
Page
of 2